Table 2.
Development progress of TIM-3 inhibitors
| Product | Company and partner (if applicable) |
Structure | TIM-3 target and ligand specificity |
Phase of development | ORR |
|---|---|---|---|---|---|
| MBG453 | Novartis | Fully humanized, undisclosed | Undisclosed | Phase I dose-escalation (NCT02608268) | Unreported |
| TSR-022 | Tesaro and GlaxoSmithKline | Fully humanized, IgG4K | Undisclosed | Phase I dose-escalation and dose-expansion (select malignancies) (NCT02817633) | All tumors: Melanoma: TSR-022 100 mg: 0/11 TSR-022 300 mg: 3/20 NSCLC: TSR-022 100 mg: 1/11 TSR-022 300 mg: 4/28 (4/12 with PD-L1+) |
| BMS-986258 (ONO7807) | Bristol Myers Squibb (five prime therapeutics) | Fully humanized, IgG1K | Undisclosed | Phase I dose-escalation (NCT03446040) | Unreported |
| INCAGN02390 | Incyte (Agenus) | Fully humanized, IgG1K | CC’-FG binding cleft and phosphatidylserine | Phase I dose-escalation (NCT03652077) | Unreported |